Understand the source comparison
Comparison with Other Myostatin Inhibition Approaches in ALS Research
ACE-031 is one of several myostatin pathway inhibitors that have been investigated in ALS or related muscle-wasting contexts. Key comparators include: Anti-myostatin antibodies (landogrozumab, domagrozumab, trevogrumab): Myostatin-specific; avoid off-target Ac
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ACE-031 is one of several myostatin pathway inhibitors that have been investigated in ALS or related muscle-wasting contexts. Key comparators include:
- Anti-myostatin antibodies (landogrozumab, domagrozumab, trevogrumab): Myostatin-specific; avoid off-target ActRIIB ligand effects but lose the activin A component that ACE-031 captures
- Follistatin: Endogenous antagonist of myostatin, activin, and GDF-11; broader than ACE-031 in some respects (also binds activin B more potently); used in AAV-delivered gene therapy approaches for muscle diseases
- Apitegromab (SRK-015): A latent myostatin inhibitor targeting the pro-myostatin/latent myostatin complex rather than mature myostatin; has entered clinical trials in SMA (spinal muscular atrophy), a motor neurone disease with genetic overlap with ALS biology
- 🔗 Also See: For broader context on myostatin inhibition research, see our Follistatin and Muscle Wasting Disease Research: Cachexia, Sarcopenia and Myostatin Inhibition Biology.